Abstract
Objectives
We aimed to compare the role of 18F-fluoride PET/CT, FDG PET/CT and 99mTc-MDP bone scans in the detection of bone metastases in patients with lung, breast and prostate carcinoma.
Methods
This was a prospective study including patients for staging (S) and restaging (R). Seventy-two patients (23S, 49R) with infiltrating ductal breast carcinoma, 49 patients (25S, 24R) with prostate adenocarcinoma and 30 patients (17S, 13R) with non-small-cell lung carcinoma (NSCLC), without known bone metastases but with high risk/clinical suspicion for the same, underwent a 99mTc-MDP bone scan, FDG PET/CT and 18F-fluoride PET/CT within 2 weeks. All scans were reviewed by two experienced nuclear medicine physicians, and the findings were correlated with MRI/thin-slice CT/skeletal survey. Histological verification was done wherever feasible.
Results
Sensitivity and negative predictive value (NPV) of 18F-fluoride PET/CT was 100 % in all three malignancies, while that of FDG PET/CT was 79 % and 73 % in NSCLC, 73 % and 80 % in breast cancer and 72 and 65 % in prostate cancer. Specificity and positive predictive value (PPV) of FDG PET/CT were 100 % in NSCLC and prostate and 97 % and 96 % in breast cancer. As compared to the 99mTc-MDP bone scan, all parameters were superior for 18F-fluoride PET/CT in prostate and breast cancer, but sensitivity and NPV were equal in NSCLC. The MDP bone scan had superior sensitivity and NPV compared to FDG PET/CT but had low specificity and PPV.
Conclusion
To rule out bone metastases in cases where there is a high index of suspicion, 18F-fluoride PET/CT is the most reliable investigation. 18F-fluoride PET/CT has the potential to replace the 99mTc-MDP bone scan for the detection of bone metastases.
Similar content being viewed by others
References
Buckwalter JA, Brandser EA. Metastatic disease of the skeleton. Am Fam Physician. 1997;55(5):1761–8.
Tritz DB, Doll DC, Ringenberg QS, Anderson S, Madsen R, Perry MC, et al. Bone marrow involvement in small cell lung cancer: clinical significance and correlation with routine laboratory variables. Cancer. 1989;63:763–6.
Bezwoda WR, Lewis D, Livini N. Bone marrow involvement in anaplastic small cell lung cancer: diagnosis, hematologic features, and prognostic implications. Cancer. 1986;58:1762–5.
Trillet V, Revel D, Combaret V, Favrot M, Loire R, Tabib A, et al. Bone marrow metastases in small cell lung cancer: detection with magnetic resonance imaging and monoclonal antibodies. Br J Cancer. 1989;60:83–8.
Perez DJ, Powles TJ, Milan J, Gazet JC, Ford HT, McCready VR, et al. Detection of breast carcinoma metastases in bone: relative merits of x-rays and skeletal scintigraphy. Lancet. 1983;2:613–6.
Rossing N, Munck O, Nielsen SP, Andersen KW. What do early bone scans tell about breast cancer patients? Eur J Cancer Clin Oncol. 1982;18:629–36.
Kunkler IH, Merrick MV. The value of non-staging skeletal scintigraphy in breast cancer. Clin Radiol. 1986;37:561–2.
Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB, et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys. 2000;48(5):1443–6.
Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171:2122–7.
Padhani A, Husband J. Bone metastases. In: Husband JES, Reznek RH, editors. Imaging in oncology oxford. UK: Isis Medical Media Ltd.; 1998. p. 765–87.
Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med. 2001;45:53–64.
Schirrmeister H, Guhlnamm A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381–9.
Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942–53.
Muindi J, Coombes RC, Golding S, Powles TJ, Khan O, Husband J. The role of computed tomography in the detection of bone metastases in breast cancer patients. Br J Radiol. 1983;56:233–6.
Karnholz R, Sze G. Current imaging in spinal metastatic disease. Semin Oncol. 1991;18:158–69.
Vanel D, Dromain C, Tardivon A. MRI of bone marrow disorders. Eur Radiol. 2000;10:224–9.
Vogler JB 3rd, Murphy WA. Bone marrow imaging. Radiology. 1988;168:679–93.
Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28–49.
Gates GF. SPECT bone scanning of the spine. Semin Nucl Med. 1998;28:78–94.
Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45:27–37.
Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305–32.
Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer. 2000;88:2927–33.
Franzius F, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med. 2000;27:1305–11.
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single and multi-field-of-view SPECT, 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.
de Jong IJ, Breeuwsma A J, Prium J, van der Jagt EJ, Jager PL, Nijman RJ et al. 18F sodium fluoride PET for the detection of bone metastases in prostate cancer. In: Prostate Cancer Symposium. 2006 ASCO; 2006.
Shreve PD, Grossmaný HB, Gross MD, Wahi RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-I[F-18]fluoro-d-glucose. Radiology. 1996;199:751–6.
Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803–9.
Pieterman RM, van Putten JWG, Meuzelaar JJ. Preoperative staging of non–small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254–61.
Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–7.
Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med. 1998;25:1244–7.
Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scans for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer. 2004;44(3):317–25.
Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of clinical value of planar bone scan, SPECT and 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800–4.
Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease with 18F-fluoride PET/CT. J Nucl Med. 2004;45:272–8.
Koichiro A, Asaki MS, Kuwabara Y, Koga H, Baba S, Hayashi K, et al. Comparison of 18FDG -PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med. 2005;19(7):575–9.
Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, et al. 18F-fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003;38(5):250–6.
Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR. 2005;184:1266–73.
Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40:1623–9.
Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, et al. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun. 2011;32(3):168–76.
Ozülker T, Küçüköz Uzun A, Ozülker F, Ozpaçac T. Comparison of 18F-FDG-PET/CT with 99mTc-MDP bone scintigraphy for the detection of bone metastases in cancer patients. Nucl Med Commun. 2010;31(6):597–603.
Krüger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36(11):1807–12.
Yen RF, Chen CY, Cheng MF, Wu YW, Shiau YC, Wu K, et al. The diagnostic and prognostic effectiveness of 18F-sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun. 2010;31(7):637–45.
Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML, et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med. 2009;50(4):501–5.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Damle, N.A., Bal, C., Bandopadhyaya, G.P. et al. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol 31, 262–269 (2013). https://doi.org/10.1007/s11604-013-0179-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11604-013-0179-7